Somatostatin Analogs Market Size, Share, And Growth Report 2032

Somatostatin Analogs Market

Somatostatin Analogs Market By type (instruments, consumables and), By Formulation (Alcohols, Iodine, Octenidine, Chlorhexidine and Others), and Application (surgeries and injections), By Region - Global And Regional Industry Overview, market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2024-2032

Category: Healthcare Report Format : PDF Pages: 130 Report Code: ZMR-4949 Published Date: Aug-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 6.77 Billion USD 13.58 Billion 8.04% 2023

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Somatostatin Analog Market, 2016–2025 (USD Million)
    • 2.2. Global Somatostatin Analog Market: Snapshot
  • Chapter 3. Global Somatostatin Analog Market – Industry Analysis
    • 3.1. Introduction
    • 3.2. Industry ecosystem analysis
    • 3.3. Deployment landscape
    • 3.4. Market Drivers
      • 3.4.1. Driver 1
      • 3.4.2. Driver 2
    • 3.5. Restraints
      • 3.5.1. Restraint 1
      • 3.5.2. Restraint 2
    • 3.6. Opportunity
      • 3.6.1. Government Funding and Support
    • 3.7. Porter’s Five forces Analysis
    • 3.8. Market Attractiveness Analysis
      • 3.8.1. Market Attractiveness Analysis by Indication
      • 3.8.2. Market Attractiveness Analysis by Type
      • 3.8.3. Market Attractiveness Analysis by Region
  • Chapter 4. Global Somatostatin Analog Market – Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Somatostatin Analog Market: Company Market Share, 2019
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Indication Launches
      • 4.2.3. Agreements, Partnerships, Cullaborations and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
    • 4.3. Price Trend Analysis
  • Chapter 5. Global Somatostatin Analog Market –Indication Analysis
    • 5.1. Global Somatostatin Analog Market Overview: by Indication
      • 5.1.1. Global Somatostatin Analog Market Share, by Indication,2019 and 2025
    • 5.2. Acromegaly
      • 5.2.1. Global Somatostatin Analog Market by Acromegaly, 2016–2025 (USD Million)
    • 5.3. NETs
      • 5.3.1. Global Somatostatin Analog Market by NETs, 2016–2025 (USD Million)
    • 5.4. Others
      • 5.4.1. Global Somatostatin Analog Market by Others, 2016–2025 (USD Million)
  • Chapter 6. Global Somatostatin Analog Market –Type Segment Analysis
    • 6.1. Global Somatostatin Analog Market Overview: by Type Segment
      • 6.1.1. Global Somatostatin Analog Market Share, by Type Segment, 2019 and 2025
    • 6.2. Octreotide
      • 6.2.1. Global Somatostatin Analog Market by Octreotide, 2016–2025 (USD Million)
    • 6.3. Lanreotide
      • 6.3.1. Global Somatostatin Analog Market # by Lanreotide, 2016–2025 (USD Million)
    • 6.4. Pasireotide
      • 6.4.1. Global Somatostatin Analog Market byPasireotide, 2016–2025 (USD Million)
  • Chapter 7. Global Somatostatin Analog Market - Regional Analysis
    • 7.1. Global Somatostatin Analog Market Overview: by Region
      • 7.1.1. Global Somatostatin Analog Marketshare, by Region, 2019 and 2025
    • 7.2. North America
      • 7.2.1. North America Somatostatin Analog Market , 2016–2025 (USD Million)
      • 7.2.2. North America Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
      • 7.2.3. North America Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.2.4. The U.S.
        • 7.2.4.1. The U.S. Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.2.4.2. The U.S. Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.2.5.2. Rest of North America Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Somatostatin Analog Market , 2016–2025 (USD Million)
      • 7.3.2. Europe Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
      • 7.3.3. Europe Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.3.4. UK
        • 7.3.4.1. U.K.Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.3.4.2. U.K. Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.3.5.2. France Somatostatin Analog Market # Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.3.6. Germany
        • 7.3.6.1. Germany Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.3.6.2. Germany Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of Europe Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.3.7.2. Rest of Europe Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Somatostatin Analog Market, 2016–2025 (USD Million)
      • 7.4.2. Asia Pacific Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
      • 7.4.3. Asia Pacific Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.4.4. China
        • 7.4.4.1. China Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.4.4.2. China Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.4.5. Japan
        • 7.4.5.1. Japan Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.4.5.2. Japan Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.4.6. India
        • 7.4.6.1. India Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.4.6.2. India Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Somatostatin Analog Market # Revenue, by Indication,2016–2025 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Somatostatin Analog Market, 2016–2025 (USD Million)
      • 7.5.2. Latin America Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
      • 7.5.3. Latin America Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil Waterrproof Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.5.4.2. Brazil Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
      • 7.5.5. Rest of Latinamerica
        • 7.5.5.1. Rest of Latinamerica Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
        • 7.5.5.2. Rest of Latinamerica Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa Somatostatin Analog Market, 2016–2025 (USD Million)
      • 7.6.2. The Middle East and Africa Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
      • 7.6.3. The Middle East and Africa Somatostatin Analog Market Revenue, by Type Segment, 2016–2025 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1. Camurus AB
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Chiasma Inc
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. CRINETICS PHARMACEUTICALS
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Dauntless Pharmaceuticals
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Ipsen Pharma
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Midatech Pharma PLC
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Novartis AG
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. Peptron, Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Pfizer Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
    • 8.10. Sun Pharmaceutical Industries Ltd
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Development

Table Of Figures

List of Figures

1. Market Research Process
2. Market Research Methodology
3. Global Somatostatin Analog Market, 2016–2025 (USD Million)
4. Porter’s Five forces Analysis
5. Global Somatostatin Analog Market Attractiveness, by Indication
6. Global Somatostatin Analog Market Attractiveness, by Type Segment
7. Global Somatostatin Analog Marketmarket Share, by Indication, 2019 and 2025
8. Global Somatostatin Analog Market by Acromegaly, 2016–2025 (USD Million)
9. Global Somatostatin Analog Market by NETs,2016–2025 (USD Million)
10. Global Somatostatin Analog Market by Others,2016–2025 (USD Million)
11. Global Somatostatin Analog Market Share, by Type Segment, 2019 and 2025
12. Global Somatostatin Analog Market by Octreotide, 2016–2025 (USD Million)
13. Global Somatostatin Analog Market by Lanreotide, 2016–2025 (USD Million) 
14. Global Somatostatin Analog Market by Pasireotide, 2016–2025 (USD Million)
15. Global Somatostatin Analog Market Share, by Region, 2019and 2025
16. North America Somatostatin Analog Market, 2016–2025 (USD Million)
17. Europe Somatostatin Analog Market , 2016–2025 (USD Million)
18. Asia Pacific Somatostatin Analog Market, 2016–2025 (USD Million)
19. Latin America Somatostatin Analog Market , 2016–2025 (USD Million)
20. The Middle East and Africa Somatostatin Analog Market , 2016–2025 (USD Million)


Table Of Tables

List of Tables

1. Global Somatostatin Analog Market: Snapshot
2. Drivers of The Somatostatin Analog Market: Impact Analysis
3. Restraints of The Somatostatin Analog Market: Impact Analysis
4. North America Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
5. North America Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
6. The U.S. Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
7. The U.S. Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
8. Rest of North America Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
9. Rest of North America Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
10. Europe Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
11. Europe Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
12. U.K. Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
13. U.K.Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
14. France Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
15. France Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
16. Germany Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
17. Germany Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
18. Rest of Europe Somatostatin Analog Market  Revenue, by Indication,2016–2025 (USD Million)
19. Rest of Europe Somatostatin Analog Market  Revenue, by Type, 2016–2025 (USD Million)
20. Asia Pacific Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
21. Asia Pacific Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
22. China Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
23. China Somatostatin Analog Market  Revenue, by Type, 2016–2025 (USD Million)
24. Japan Somatostatin Analog Market  Revenue, by Indication,2016–2025 (USD Million)
25. Japan Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
26. India Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
27. India Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
28. Rest of Asia Pacific Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
29. Rest of Asia Pacific Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
30. Latin America Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
31. Latin America Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
32. Brazil Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
33. Brazil Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
34. Rest of Latin America Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
35. Rest of Latin America Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
36. The Middle East and Africa Somatostatin Analog Market Revenue, by Indication,2016–2025 (USD Million)
37. The Middle East and Africa Somatostatin Analog Market Revenue, by Type, 2016–2025 (USD Million)
 

Methodology

FrequentlyAsked Questions

Somatostatin analogs are synthetic drugs designed to mimic the action of somatostatin, a hormone that inhibits the release of several other hormones, including growth hormone, insulin, and glucagon.

According to study, the Somatostatin Analogs Market size was worth around USD 6.77 billion in 2023 and is predicted to grow to around USD 13.58 billion by 2032.

The CAGR value of Somatostatin Analogs Market is expected to be around 8.04% during 2024-2032.

North America has been leading the Somatostatin Analogs Market and is anticipated to continue on the dominant position in the years to come.

The Somatostatin Analogs Market is led by players like Camurus AB, Chiasma Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Ipsen Pharma, Midatech Pharma PLC, Novartis AG, Peptron Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Teva Pharmaceuticals Inc, amongst others.

  • zion payment modes

List of Contents

Market SizeOverviewSegmentationReport ScopeGlobal Market Size: Regional AnalysisMarket Size: Competitive PlayersThe Global Market is segmented as follows:

HappyClients